In the years after surgery, micro- and macronutrient impairments present a significant risk. Dr David Johnson tells you how to identify signs of trouble.

Drs Shubrook and Skolnik discuss the role of GLP-1 receptor agonists in the management of type 2 diabetes and the surprising benefits of these agents when combined with insulin.

The FDA's recent addition of a cardiovascular indication for diabetes drug empagliflozin is a significant milestone in diabetes care, says Dr Anne Peters.

So many choices! A diabetes expert provides tips on selecting a basal insulin for a patient with diabetes.

The healthy feet of patients with prediabetes represent a special opportunity for medical providers, says Dr Anne Peters.

The positive effects of empagliflozin on renal disease are discussed by Dr Christoph Wanner, one of the lead authors of the EMPA-REG OUTCOME trial.

Will ultra-long-acting insulin become the basal insulin of choice? Dr Carol Wysham discusses results of SWITCH 2 at EASD 2016.

Applause again rang out over new drug data presented at EASD 2016, but meeting organizer Per-Henrik Groop says diabetes research was the real star of the conference.

The key to slowing the progression of type 2 diabetes may be 'resting' the pancreatic beta cells early in the disease rather than stimulating them to produce more insulin, says Dr Steven Kahn.

Dr Mandrola interviews the principal investigator of a new study showing that long-term low systolic blood pressure and LDL cholesterol dramatically reduces the risk for CV events.